Filing summary
Issuer and period: The supplied filing is Virios Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2021—not a filing under the name Dogwood Therapeutics, Inc. The issuer-name discrepancy should be verified.
Business context
Virios is a pre-revenue, development-stage biotechnology company developing IMC-1, a fixed-dose combination of famciclovir and celecoxib, for fibromyalgia. Its proposed approach is to suppress HSV-1 activation and replication. The company reported no revenue for the three- or nine-month periods.
Financial performance and position
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $2.96 million | $0.11 million | $7.88 million | $0.16 million |
| General and administrative | $1.15 million | $2.55 million | $3.58 million | $3.42 million |
| Total operating expenses | $4.11 million | $2.66 million | $11.45 million | $3.58 million |
| Net loss | $4.11 million | $2.72 million | $11.45 million | $3.85 million |
| Basic and diluted loss per share | $0.49 | $0.56 | $1.37 | $0.80 |
Gross margin and operating margin are not applicable because the company reported no revenue. At September 30, 2021, cash was $19.19 million, current assets were $20.11 million, current liabilities and total liabilities were $1.23 million, and stockholders’ equity was $18.88 million. The filing reports no debt outstanding.
For the first nine months of 2021, operating cash use was $10.51 million, financing cash use was $0.10 million, and cash declined by $10.61 million from $29.80 million at year-end 2020. The company received $0.20 million from warrant exercises and paid $0.30 million of IPO costs.
Changes and notable items
- R&D rose substantially year over year, primarily from clinical-trial costs, toxicology studies, salaries, and drug development and manufacturing. Management attributed Q3 G&A’s year-over-year decline mainly to lower compensation expense; the comparable 2020 period included $2.0 million of founder equity compensation.
- Accumulated deficit increased to $39.41 million from $27.97 million at December 31, 2020. Shares outstanding at September 30 were 8,330,390.
- The company said approximately 40% of planned FORTRESS Phase 2b participants had been enrolled. The trial targets 460 female patients; management projected top-line results in Q3 2022.
- Management reported that two-species chronic toxicology studies were progressing as planned, with completion expected in Q3 2022. A September 2021 patent grant for a valacyclovir-celecoxib candidate extended exclusivity to 2033, according to the filing.
Outlook, risks, and contingencies
Management estimated that September 30 cash would fund operations and capital requirements for at least 12 months, including completion of FORTRESS and planning for a Phase 3 study. The company expects continuing losses, will need additional capital to complete clinical development and pursue commercialization, and had no committed external funding. Future financing may not be available on acceptable terms.
The filing identifies potential clinical-trial, regulatory, third-party execution, financing, and pandemic-related risks. Virios said COVID-19 had not materially affected operations to date but could disrupt enrollment or timelines. Torreya Capital LLC sought $1.035 million plus arbitration costs in a dispute over an alleged IPO advisory fee; the company called the claim baseless and said it would defend itself.
Management concluded disclosure controls were not effective at a reasonable assurance level because of a continuing material weakness involving segregation of duties, financial reporting, and general technology controls. Remediation steps were underway, but the company said it could not assure they would be sufficient. The filing reported no material off-balance-sheet arrangements.
Important facts for investors to verify
- Whether this Virios Therapeutics filing is the intended filing for Dogwood Therapeutics, Inc.
- Actual FORTRESS enrollment, trial completion, and reported results versus management’s Q3 2022 projection.
- Cash burn and available runway, and whether additional financing is needed or secured.
- Outcome and potential financial impact of the Torreya arbitration claim.
- Progress in remediating the material weakness and the effectiveness of the related controls.
- Clinical and regulatory progress for IMC-1 and completion of the chronic toxicology studies.